Celldex Therapeutics 3Q Loss/Shr 96c >CLDX

Celldex reported no revenue in the quarter, unchanged from a year earlier, while its net loss widened. Higher barzolvolimab-related research and development spending and increased general and administrative expenses drove the loss increase.Financial Highlights¹ Reported as “Total revenues”. ² Repor…